• 1
    Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998; 128:922930.
  • 2
    Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. Lancet 2004; 363:959969.
  • 3
    Centers for Disease Control and Prevention. Human Rabies—Florida, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:767769.
  • 4
    Centers for Disease Control and Prevention. Human Rabies—New Hampshire 1996. MMWR Morb Mortal Wkly Rep 1997; 46:267270.
  • 5
    Mitmoonpitak C, Wilde H, Tepsumetanon W. Current status of animal rabies in Thailand. J Vet Med Sci 1997; 59:457460.
  • 6
    Centers for Disease Control and Prevention. Human Rabies Prevention—United States, 1999: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 1999; 48:121.
  • 7
    LeGuerrier P, Pilon PA, Deshaies D, et al. Pre-exposure prophylaxis for the international traveler: a decision analysis. Vaccine 1996; 14:167176.
  • 8
    Nicholson KG, Turner GS, Aoki FY. Immunization with a human diploid cell strain of rabies vaccine: two-year results. J Infect Dis 1978; 137:783788.
  • 9
    Pandey P, Shlim DR, Cave W, et al. Risk of possible exposure to rabies among tourists and foreign residents in Nepal. J Travel Med 2002; 9:127131.
  • 10
    Wilde H, Briggs DJ, Meslin FX, et al. Rabies update for travel medicine advisors. Clin Infect Dis 2003; 37:96100.
  • 11
    Moran GJ, Taln DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. JAMA 2000; 284:10011007
  • 12
    Hoey J, Todkill A. Fatal case of rabies. Can Med Assoc J 1997; 156:13111312. (Editorial)
  • 13
    Strady C, Jaussaud R, Beguinot I, et al. Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 2000; 18:26612667.
  • 14
    Strady A, Lang J, Lienard M, et al. Antibody persistence following pre-exposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998; 177:12901295.
  • 15
    Gherardin AW, Scrimgeour DJ, Lau SC, et al. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine. J Travel Med 2001; 8:122126.
  • 16
    Jaijaroensup W, Limusanmo S, Khawplod P, et al. Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. J Travel Med 1999; 6:234237.
  • 17
    Briggs DJ, Schwenke JR. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine 1992; 10:125129.
  • 18
    Fishbein DB, Dressen DW, Holmes F, et al. Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. Vaccine 1989; 7:437442.
  • 19
    Lau C, Sisson J. The effectiveness of intradermal pre-exposure rabies vaccination in an Australian travel medicine clinic. J Travel Med 2002; 9:285288.
  • 20
    Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001; 33:15531566.